ACTRN12605000594628
Recruiting
N/A
A pilot study to evaluate the feasibility, safety and efficacy of psychotherapeutic intervention for comorbid BPD and first-episode psychosis
Orygen Research Centre and Orygen Youth Health0 sites16 target enrollmentOctober 5, 2005
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Borderline Personality Disorder
- Sponsor
- Orygen Research Centre and Orygen Youth Health
- Enrollment
- 16
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Eligibility for EPPIC program, 1 week or more of psychotic symptoms with less than 6 months of active previous treatment (i.e., antipsychotic medication); and (2\) Diagnosis of four or more DSM\-IV BPD traits (APA, 1994\).
Exclusion Criteria
- •(1\) Severe and enduring psychotic symptoms, defined as scores of 4 or more on 1 or more psychotic items of the Brief Psychiatric Rating Scale (BPRS) which have persisted for more than 1 month (Overall \& Gorham, 1962\); (2\)Unable to converse in, or read English without an interpreter; (3\) Intellectual deficits, such that unable to meaningfully participate in the psychotherapy; and (4\) Already given informed consent for another psychotherapy trial at ORYGEN Youth Health, or already received a course of CAT.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 2
A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomyProstate cancerCancer - ProstateACTRN12607000082404rology Department The Royal Melbourne Hospital15
Recruiting
Phase 1
A pilot study of patients with oligometastases from breast cancer treated with stereotactic ablative body radiosurgery in combination with the anti-PD-1 antibody MK-3475.Metastatic Breast Cancer (1-5 metastases)Cancer - BreastCancer - BoneACTRN12614001181695Peter MacCallum Cancer Centre15
Recruiting
N/A
A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using Indocyanine green.NL-OMON24349Meander Medical Centre, Department of Surgery10
Active, Not Recruiting
Phase 1
Identification of the sentinel lymph node (SLN) in patients with colon carcinoma.Colon carcinomaTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]EUCTR2021-006796-41-NLMeander Medical Centre5
Completed
N/A
A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CWcolon carcinomaintestinal cancer1001799010017991NL-OMON53524Meander Medisch Centrum5